0001209191-23-018875.txt : 20230315
0001209191-23-018875.hdr.sgml : 20230315
20230315160013
ACCESSION NUMBER: 0001209191-23-018875
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230313
FILED AS OF DATE: 20230315
DATE AS OF CHANGE: 20230315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Delfini Lisa
CENTRAL INDEX KEY: 0001873253
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38886
FILM NUMBER: 23735037
MAIL ADDRESS:
STREET 1: C/O TREVI THERAPEUTICS, INC.
STREET 2: 195 CHURCH STREET, FL. 14
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Trevi Therapeutics, Inc.
CENTRAL INDEX KEY: 0001563880
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450834299
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 195 CHURCH STREET
STREET 2: 14TH FLOOR
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-304-2499
MAIL ADDRESS:
STREET 1: 195 CHURCH STREET
STREET 2: 14TH FLOOR
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-13
0
0001563880
Trevi Therapeutics, Inc.
TRVI
0001873253
Delfini Lisa
C/O TREVI THERAPEUTICS, INC.
195 CHURCH STREET, 14TH FLOOR
NEW HAVEN
CT
06510
0
1
0
0
Chief Financial Officer
Common Stock
2023-03-13
4
M
0
2291
0.511
A
25629
D
Common Stock
2023-03-13
4
S
0
892
1.7532
D
24737
D
Stock Option (right to buy)
0.511
2023-03-13
4
M
0
2291
0.00
D
2032-02-10
Common Stock
2291
80209
D
This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan.
Includes 4,312 shares purchased through the Issuer's employee stock purchase plan.
This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on March 13, 2023.
This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.
/s/ Christopher Galletta, attorney-in-fact
2023-03-15